Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

J von Pawel, U Gatzemeier, JL Pujol… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: Topotecan, administered intravenously, is active in small-cell lung cancer
(SCLC). In this study, the comparability of oral topotecan to IV topotecan was investigated …
被引用次数：267 相关文章
[PDF] researchgate.net

[PDF][PDF] Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

J von Pawel, U Gatzemeier, JL Pujol… - Journal of Clinical …, 2001 - researchgate.net
Purpose: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC).
In this study, the comparability of oral topotecan to IV topotecan was investigated. Patients …

Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

J Von Pawel, U Gatzemeier, JL Pujol, L Moreau… - 2001 - christie.openrepository.com
PURPOSE: Topotecan, administered intravenously, is active in small-cell lung cancer
(SCLC). In this study, the comparability of oral topotecan to IV topotecan was investigated …

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

J von Pawel, U Gatzemeier, JL Pujol… - Journal of clinical …, 2001 - pubmed.ncbi.nlm.nih.gov
Purpose Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC).
In this study, the comparability of oral topotecan to IV topotecan was investigated. Patients …

[引用][C] Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

J VON PAWEL, U GATZEMEIER… - Journal of clinical …, 2001 - pascal-francis.inist.fr
Phase II comparator study of oral versus intravenous topotecan in patients with
chemosensitive small-cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and …

Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

J Von Pawel, U Gatzemeier… - Journal of Clinical …, 2001 - research.manchester.ac.uk
Purpose: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC).
In this study, the comparability of oral topotecan to IV topotecan was investigated. Patients …

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

J von Pawel, U Gatzemeier, JL Pujol… - Journal of Clinical …, 2001 - europepmc.org
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive
small-cell lung cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

[引用][C] Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

J VON PAWEL, U GATZEMEIER… - Journal of …, 2001 - American Society of Clinical …